Pliant Therapeutics (PLRX) Receivables - Net (2019 - 2023)

Pliant Therapeutics (PLRX) has 5 years of Receivables - Net data on file, last reported at $1.6 million in Q2 2023.

• Receivables - Net for Q2 2023 came in at $1.6 million, down 68.33% year-over-year; the trailing twelve-month figure through Jun 2023 was $1.6 million (down 68.33% YoY), and the FY2022 annual result was $2.0 million, down 0.75% from the prior year.
• Receivables - Net fell to $1.6 million in Q2 2023 per PLRX's latest filing, from $3.3 million in the prior quarter.
• Over five years, Receivables - Net peaked at $9.3 million in Q4 2020 and troughed at $1.2 million in Q1 2022.
• A 5-year average of $3.5 million and a median of $2.1 million in 2021 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2021 and 2022: Receivables - Net slumped 78.47% in 2021, then surged 172.62% in 2022.
• A 5-year view of Receivables - Net shows it stood at $7.1 million in 2019, then jumped by 31.58% to $9.3 million in 2020, then tumbled by 78.47% to $2.0 million in 2021, then declined by 0.75% to $2.0 million in 2022, then retreated by 20.32% to $1.6 million in 2023.
• Business Quant data shows PLRX's Receivables - Net at $1.6 million in Q2 2023, $3.3 million in Q1 2023, and $2.0 million in Q4 2022.